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Human papillomavirus (HPV) represents an exciting subject
of study because it is currently established as an essential
etiological factor of uterine cervical cancer and strongly
implicated in the development of other genital cancers
as well, in addition to benign genital warts. Additionally,
substantial amount of new data have been elaborated linking
HPV with head and neck cancer and, more tentatively, also
with esophageal, breast, prostate, and lung cancers. Despite
the existing controversies, the possible link of HPV infection
with these nongenital carcinomas opens a new fascinating era
of HPV research.
Concomitantly, the HPV vaccination has emerged as a
new paradigm to cancer prevention programs worldwide. As
much as 10% of all cancers can be related to certain HPV
types, and therefore we can anticipate a substantial reduction
in cancers worldwide with the implementation of HPV
prophylactic vaccines. HPV vaccination provides a realistic
option to reduce cervical cancer incidence and mortality
in poor and developing countries, where the secondary
prevention options (i.e., the screening by Papanicolaou
smears and HPV testing) are not easily implemented due
to lacking infrastructure, low human resources, lack of
population adherence, and lack of political commitment. We
can anticipate substantial reduction of HPV-related diseases.
During the past decades, HPV research has been pursued
along diﬀerent lines, which has resulted in an ever-increasing
number of publications dissecting the multifaceted mecha-
nisms of HPV infections and the complexity of biological
cascade related to HPV-associated human carcinogenesis.
We are pleased to introduce this special issue dedicated
to Papillomavirus, from the bench to the clinics, providing
us an opportunity of entering this fascinating world that
integrates a plethora of specialties studying the relation
between this virus and human cancer.
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